Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Posted by Tech Dows on Jan 16th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00. Following the transaction, the president now owns 2,911,138 shares of the company’s stock, valued at $31,585,847.30. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Songjiang Ma also recently made the following trade(s):

On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total value of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total transaction of $24,800.00.
On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total transaction of $25,000.00.
On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00.
On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total value of $24,540.00.
On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.82, for a total value of $21,640.00.
On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Price Performance

Gyre Therapeutics stock traded down $0.13 during trading on Thursday, reaching $10.80. The company had a trading volume of 78,155 shares, compared to its average volume of 141,994. The firm’s 50-day simple moving average is $11.74 and its 200 day simple moving average is $12.65. Gyre Therapeutics, Inc. has a 1-year low of $8.26 and a 1-year high of $26.37.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC purchased a new stake in shares of Gyre Therapeutics during the third quarter worth $47,000. Barclays PLC grew its stake in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares in the last quarter. Rhumbline Advisers acquired a new stake in Gyre Therapeutics in the 2nd quarter valued at about $123,000. Renaissance Technologies LLC purchased a new position in Gyre Therapeutics in the 2nd quarter worth approximately $166,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $218,000. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.